The association between systemic anticancer therapy (SACT) at the end of life (EOL) and acute care use among patients treated at oncology practices participating in the Oncology Care Model (OCM).
Canavan M, Sheth K, Scott J, Westvold S, Adelson K. The association between systemic anticancer therapy (SACT) at the end of life (EOL) and acute care use among patients treated at oncology practices participating in the Oncology Care Model (OCM). Journal Of Clinical Oncology 2023, 41: 6580-6580. DOI: 10.1200/jco.2023.41.16_suppl.6580.Peer-Reviewed Original ResearchSystemic anticancer therapyDay of deathOncology Care ModelEnd of lifeAcute care useIntensive care unitInpatient admissionsED visitsCare useReceipt of chemotherapyAcute care utilizationEmergency department useProportion of decedentsRates of chemotherapyChi-square testICU stayIO therapyCare unitCare utilizationInpatient stayCT patientsDepartment useHospice useCare metricsOncology practiceThe impact of receipt of systemic anticancer therapy (SACT) near the end of life (EOL) on cost among oncology practices participating in CMS' Oncology Care Model (OCM).
Adelson K, Canavan M, Sheth K, Scott J, Westvold S. The impact of receipt of systemic anticancer therapy (SACT) near the end of life (EOL) on cost among oncology practices participating in CMS' Oncology Care Model (OCM). Journal Of Clinical Oncology 2023, 41: e18923-e18923. DOI: 10.1200/jco.2023.41.16_suppl.e18923.Peer-Reviewed Original ResearchSystemic anticancer therapyDay of deathOncology Care ModelEnd of lifeAcute care useSystemic therapyCT patientsCare useImpact of receiptMean episode costReceipt of chemotherapyReceipt of immunotherapyICU useED costsIO patientsPharmacy costsOncology practiceEpisode costsTreatment decisionsDownstream careCare modelAmbulatory settingPart BPatientsImmunotherapy